Global Type 2 Diabetes Report 2016 - Therapeutics Pipeline Review of 200+ Companies & Drug Profiles - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "Type 2 Diabetes - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Type 2 Diabetes , complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Type 2 Diabetes and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Type 2 Diabetes Overview
  3. Therapeutics Development
  4. Pipeline Products for Type 2 Diabetes - Overview
  5. Pipeline Products for Type 2 Diabetes - Comparative Analysis
  6. Type 2 Diabetes - Therapeutics under Development by Companies
  7. Type 2 Diabetes - Therapeutics under Investigation by Universities/Institutes
  8. Type 2 Diabetes Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Type 2 Diabetes - Products under Development by Companies
  13. Type 2 Diabetes - Products under Investigation by Universities/Institutes
  14. Type 2 Diabetes - Companies Involved in Therapeutics Development
  • Addex Therapeutics Ltd
  • Adocia
  • Advinus Therapeutics Ltd.
  • Aegis Therapeutics, LLC
  • AFFiRiS AG
  • Alchemia Limited
  • Alize Pharma SAS
  • AlphaMab Co., Ltd
  • Amarantus Bioscience Holdings, Inc.
  • Ambrx, Inc.
  • Amgen Inc.
  • Anchor Therapeutics, Inc.
  • AntriaBio, Inc.
  • Aphios Corporation
  • Araim Pharmaceuticals, Inc.
  • Arisaph Pharmaceuticals, Inc.
  • ArisGen SA
  • Array BioPharma Inc.
  • Artery Therapeutics, Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • AUS Bio Limited
  • Avaxia Biologics, Inc.
  • Bayer AG
  • Beta-Cell NV
  • Betagenon AB
  • Biocon Limited
  • Biodel Inc.
  • Biogenomics Limited
  • BioLingus AG
  • BioRestorative Therapies, Inc.
  • BioTherapeutics Inc.
  • BioTime, Inc.
  • Biscayne Pharmaceuticals, Inc.
  • Boehringer Ingelheim GmbH

For more information visit http://www.researchandmarkets.com/research/3qn64l/type_2_diabetes

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716